Drugs / SABIN monovalent OPV2
SABIN monovalent OPV2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02521974 | Oct 2015 → Jul 2016 | post-vaccinal encephalitis | Fidec Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SABIN monovalent OPV2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02521974 ↗ |
| Known as | mOPV2 | “To generate data on immunogenicity, safety, and genetic stability on the Sabin 2 vaccine (mOPV2) and as a future comparator for new polio vaccine research after the global...” NCT02521974 ↗ |
| Known as | Sabin 2 | “To generate data on immunogenicity, safety, and genetic stability on the Sabin 2 vaccine (mOPV2) and as a future comparator for new polio vaccine research after the global...” NCT02521974 ↗ |
| Modality | Vaccine | “poliomyelitis virus vaccine” NCT02521974 ↗ |
| Route | Oral | “Polio Sabin™ Mono Two (oral)” NCT02521974 ↗ |